Introduction
Chronic obstructive pulmonary disease (COPD) remains associated with high morbidity and mortality. According to the World Health Organisation (WHO), in 2020 COPD will rank fifth worldwide in burden of disease. Furthermore, it is a leading cause of death and expected to become the seventh leading cause of disabilityadjusted life years lost [1, 2] . In Switzerland, around 200,000-300,000 patients suffer from COPD of GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage II or higher [3] .
Many COPD patients experience exacerbations of the disease. The GOLD defines COPD exacerbation as "an acute event characterized by a worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to change of the medication" [4] . The clinical presentation for exacerbations of COPD is heterogeneous and can be triggered by infectious and noninfectious conditions. Determining the cause of the exacerbation is challenging, and thus far there are no tools capable of diagnosing or predicting the duration of an acute exacerbation of COPD (AECOPD) [5] . AECOPDs requiring hospital admission are considered to be severe and are associated with increased mortality [6] as well as with an increased mortality risk of 30-43% within the 12 months following the AECOPD [6] [7] [8] . There is a direct correlation between the number of severe AECOPDs and the mortality rate among hospitalized patients with COPD [9] . The administration of noninvasive ventilation (NIV) to hypercapnic patients decreases the mortality rate by 21% [10] , which strongly suggests that in-hospital management directly influences the prognosis of patients with severe AECOPD. Therefore, it is of paramount importance to provide adequate and comprehensive treatment to this severely affected patient population.
The European COPD Audit initiated by the European Respiratory Society (ERS) in collaboration with the Forum of European Respiratory Societies (FERS) aimed to monitor the management of severe AECOPD in 13 European countries (Austria, Belgium, Croatia, Greece, Malta, Poland, Ireland, Romania, Slovakia, Spain, Switzerland, Turkey, and the UK) [11] [12] [13] . In Switzerland, patients were recruited from 19 hospitals distributed throughout 13 Swiss cantons.
Data on the management of AECOPD in Switzerland are scarce. Thus, the aim of this study was to examine the quality of care for AECOPD in Swiss hospitals in light of the GOLD 2010 guidelines and to provide specific recommendations for the management of severe AECOPD in Switzerland.
Materials and Methods
The study was classified as a quality control study by the Ethics Committee of Basel (307/10), and as such, no patient consent was required.
The full methodology of the study has been reported [12] . Patients requiring hospital admission due to AECOPD during a predefined 2-month period in 2011 at 19 Swiss hospitals (Kantonsspital Aarau, Universitätsspital Basel, St. Claraspital Basel, Spital Bern-Tiefenau, Inselspital Bern, Kantonsspital Chur, Kantonsspital Liestal, Kantonsspital Bruderholz, Spitalzentrum Biel, Spital Laufenburg, Lungenpraxis Hirslanden -Klinik St. Anna Luzern, Luzerner Höhenklinik Montana, Zuger Kantonsspital, Bürger-spital Solothurn, Kantonsspital St. Gallen, Spital Thun, Kantonsspital Münsterlingen, GZO Spital Wetzikon, and Lungenzentrum Hirslanden Zürich) were considered eligible for the study. The inclusion and exclusion criteria have been reported previously [12] . In short, patients who were admitted to the hospital for ≥ 12 h with a senior clinician-made diagnosis of COPD exacerbation or any other synonym, confirmed at discharge by the investigator/audit lead, and patients who were admitted to the hospital for ≥ 12 h with a respiratory cause of admission as indicated by the discharge report and a history compatible with COPD were included in the study. Most of the Swiss hospitals from which patients were recruited were located in the German-speaking areas of Switzerland. The hospital catchment population was 3,524,177 citizens [12] .
The cases were examined by a respiratory specialist in charge of the emergency ward. When an exacerbation was identified, detailed demographic and medical history data were collected and entered into a Web-based application. Data collection and imputation were standardized and centrally managed by a trained professional. The follow-up period was 90 days. Figure 1 depicts the flowchart for patient inclusion in the study.
The following GOLD recommendations were investigated according to the European COPD Audit Study data: (1) symptoms; (2) arterial blood gas results; (3) chest radiograph results; (4) medical treatment; (5) oxygen therapy; and (6) type of mechanical ventilation [12] .
Statistical Analysis
Differences in dichotomous variables were evaluated using the χ 2 test or Fisher's exact test, as appropriate. Normally distributed parameters were analyzed using the Student t test for equality of means. All other continuously nonnormally distributed parameters were evaluated using the nonparametric Mann-Whitney U test or the Kruskal-Wallis test, as appropriate.
The Statistical Package for the Social Sciences (SSPS Inc., version 19 and 23 for Windows) was used. All tests were two-tailed; a p value of <0.05 was considered significant. The results are expressed as mean (standard deviation) or median and interquartile range, unless otherwise stated.
Results

Patient Characteristics
A total of 307 Swiss patients were included in the database, and the data on 295 patients were analyzed ( Fig. 1 ) . Six of the discharged patients had been misdiagnosed, 1 died, 1 left within the first 12 h of hospitalization, 3 were moved to a nonparticipating hospital, and 1 had an incorrect admission date. The most frequent comorbidities are shown in Figure  2 . Congestive heart failure ( p < 0.001), metastatic solid malignancy ( p < 0.001), dementia ( p < 0.001), and renal disease ( p < 0.001) were significantly more common in the Swiss patients than in the patients from the other European countries. Conversely, myocardial infarction ( p < 0.001), cerebrovascular disease ( p = 0.006), and ulcer disease ( p = 0.011) were more common in the other European countries than in Switzerland.
Organization and Resources
The organization and resources of the hospitals caring for AECOPD patients in Switzerland and in other countries of Europe are depicted in Table 2 . The resources of the Swiss hospitals were superior or equivalent to those of the other European hospitals in several categories ( Table 2 ) . NIV was available in 100% of the participating Swiss hospitals compared to 86.9% of the hospitals in the other European countries ( p = 0.417). In 94.7% of the Swiss hospitals, a high dependency unit was available, compared to 47.1% of the hospitals in the other European countries ( p = 0.001). In Switzerland, patients have access to a pulmonary rehabilitation program in 89.5% of the participating hospitals, compared to 48.1% of the participating hospitals in the other European countries ( p = 0.004). There were also significant differences in the types of rehabilitation program offered, with home-based therapy being the most prominent program offered in Switzerland compared to the other European countries (68.4 vs. 4.8%). A hospitalbased program was the main therapy in the other European countries compared to Switzerland (17.7 vs. 5.3%). 
Pharmacological Treatment for COPD before Admission, during Hospitalization, and after Discharge
The prescribed pharmacological therapy for COPD before, during, and after hospital admission in Switzerland and the other European countries is presented in Table 3 . Differences were noted in the frequency of theophylline administration before admission (3.7 vs. 16.6%; p < 0.001), during hospitalization (1.0 vs. 14.5%; p < 0.001), and after discharge (3.1 vs. 20.2%; p < 0.001) be- Values are presented as n (%). LABA, long-acting β 2 -agonist; ICS, inhaled corticosteroids; LAMA, long-acting muscarinic antagonist (anticholinergic); SABA, short-acting β 2 -agonist; SAMA, short-acting muscarinic antagonist; IVS, invasive ventilatory support; NIV, noninvasive ventilatory support.
Implementation of the GOLD Recommendations for the Treatment of COPD Exacerbations
The implementation of the GOLD recommendations for AECOPD treatment in Switzerland and in other European countries is presented in Figure 3 
Outcomes
The outcomes of the patients with severe AECOPD included in the audit in Switzerland and in the other European countries are presented in Table 4 . In Switzerland, the patients had a prolonged hospital length of stay (on average 11.3 vs. 8.7 days; p < 0.001), but a lower 90-day readmission rate (25.4 vs. 35.3%; p = 0.003). Although the overall mortality rate tended to be lower in Switzerland (8.1%) than in the other European countries (10.9%), Switzerland had a slightly higher rate of in-hospital deaths (5.4%) than the other European countries (4.9%).
Discussion
The European COPD Audit provided a unique overview of the management of exacerbations of COPD and their outcomes in Europe. The Swiss COPD Audit comprised 19 hospitals, thus representing the only available multicenter study in the country focusing specifically on the management of COPD exacerbations. Although the number of patients included was relatively modest and represented only 50% of the Swiss population, the Swiss COPD Audit offered objective data for the formation of action plans for exacerbation care in Switzerland.
A reliable diagnosis and accurate therapy are essential to improve patient outcomes after COPD exacerbation [4] . The diagnosis of COPD and the clinical diagnosis of exacerbation of COPD both benefit from spirometric information. The absence of this information at admission may lead to incorrect diagnosis and treatment especially, since spirometry is not recommended during an acute exacerbation [4] . That said, 36% of the Swiss patients did not have any spirometry results available at admission, although the Swiss hospitals were better equipped than those of the other European countries.
Pulmonary rehabilitation improves the exercise capacity and quality of life of a patient [15] . Although pulmonary rehabilitation was available in 89.5% of all Swiss hospitals, only 40% of the patients took advantage of this therapeutic option. This could be attributed to the following: (1) pulmonary rehabilitation is not reimbursed by health insurance for any patients with mild disease; (2) pulmonary rehabilitation is offered as ambulatory treatment and many patients are too sick with too many comorbidities to be able to attend; and/or (3) physicians do not prescribe the rehabilitation program.
Evaluation of the severity of an exacerbation requires a blood gas analysis, particularly in those patients with hypoxemia as evidenced by transcutaneous oximetry [4] . It is especially striking that although a blood gas analysis is recommended in the GOLD guidelines [1] , this examination was performed on only 85.6% of the patients fulfilling the criteria for severe exacerbation and thus requiring hospitalization. NIV reduces the mortality rate and the length of ICU and hospital stay [16] ; yet only 66.7% of the patients fulfilling the ABG criteria for NIV received this therapy, and only 30.0% of those requiring IMV were treated accordingly. In the other European countries, NIV was administered to only 51.3% of the patients fulfilling the ABG criteria, and IMV to only 15.2% of the patients. NIV was, however, only available in 89.1% of the hospitals in the other European countries, and this could partly account for the lack of administration of this treatment in those countries. In Switzerland, NIV was available in all the participating hospitals.
Antibiotic use was significantly lower in the Swiss hospitals during hospitalization and after discharge, compared to the rest of Europe. The GOLD guidelines state that antibiotics should be administered when a bacterial infection is suspected [1] . With the increased usage of faster and more efficient molecular techniques, such as polymerase chain reaction, for detecting the type and presence of bacterial infections, as well as the use of circulating blood C-reactive protein (CRP) and procalcitonin (PCT) levels for determining the initiation of antibiotic administration, antibiotic usage can be decreased [17, 18] . In view of the threat of an increase in antibiotic-363 resistant bacteria, less antibiotic usage during an exacerbation of COPD should be considered by the other European countries.
Administration of systemic corticosteroids before hospital admission was significantly higher in Switzerland than in the other European countries, but during hospitalization and after discharge, the Swiss patients were administered less systemic corticosteroids than the patients in the other European countries. The increased use of corticosteroids before admission may be due to the national model of care in Switzerland, where most patients referred for hospital admission have already been seen and have usually been treated by their general practitioner.
In accordance with the GOLD report 2010, fewer methylxanthines were used as a treatment option in Switzerland compared to the other European countries. Although more methylxanthines were used in the other European countries, the 90-day readmission and follow-up mortality rates were significantly higher than in Switzerland. According to the GOLD recommendations, the beneficial effects of methylxanthines on lung function and other clinical end points are modest and inconsistent [1] . Recent data showing the effects of methylxanthines on inflammation and fibrosis may account for the increased use of methylxanthines in the other European countries [19] [20] [21] .
More Swiss patients had consolidation than had patients from the other European countries. Saleh et al. [22] found that patients with COPD exacerbation who have consolidation have a more severe disease and worse prognosis than patients without consolidation. This could account for the longer hospital stay experienced by the Swiss patients compared to the patients from the other European countries.
There were significant differences in the prevalence of comorbidities between the Swiss patients and the patients from the other European countries. These differences may be due to differences in the complexity of workups in the various health-care systems across Europe. Since there are so many significant differences in treatment before and during hospitalization, it is difficult to determine which aspect of the treatment resulted in longer hospitalization, decreased readmission, and decreased follow-up mortality. It is also possible that these differences merely reflect different health-care models, as the length of hospital stay is not only determined by the severity of the disease but also by social and logistic factors facilitating home or institutional care.
Swiss Recommendations for an Action Plan for AECOPDs
Based on the available literature, collected data, and workshops involving respiratory physicians (hospital managers) representing all recruiting institutions, the following recommendations were established for the management of exacerbations of COPD in Switzerland. It is important to note that these recommendations may not be generalizable to all institutions in Switzerland. 1 Smoking cessation and vaccination information should be offered to COPD patients admitted to the hospital for exacerbation. Patients should be offered smoking cessation counselling and information regarding influenza and pneumococcal vaccination every time they are admitted to the hospital with an exacerbation. However, at the moment there is no reimbursement for non-physician smoking cessation counselling in the Swiss health care system, which may deter the introduction of this action [23] . We, therefore, additionally recommend including non-physician smoking cessation support in the Swiss tariff system and the fostering of a closer cooperation with the Swiss lung organization (Lungenliga). 2 ABG or venous blood gas should be measured. Patients' blood gas should be evaluated at presentation. The treatment and the diagnosis of exacerbation of COPD are very dependent on the blood gas analysis results; thus, for every patient with suspicion of severe exacerbation of COPD, we recommend that at least a venous blood gas analysis be performed [24, 25] . 3 Medical staff should be trained in administering bronchodilators through a nebulizer with oxygen in the emergency ward. Patients should be offered oxygen at presentation. The cornerstone of treatment for AECOPD is bronchodilation with short-acting β 2 -agonists at an increased dosis and frequency [4] . Medical staff should be trained in administering bronchodilators through a nebulizer with oxygen in the emergency ward to facilitate fast and correct therapy. 4 Systemic steroids should be administered. Patients should receive systemic steroids. Systemic steroids are efficient in the treatment of AECOPD, and they should be administered if there is a reasonable suspicion for an AECOPD. They reduce the recovery time of FEV 1 , hospital length of stay, and mortality rate [26] . The main effect of the steroids shows in the first 72 h of exacerbation. Based on the newest literature, we recommend a dose of 20-60 mg prednisone for 5 days [3, [27] [28] [29] . [32] [33] [34] [35] [36] . In this study, it was found that patients administered NIV had a survival probability of 80.4%, compared to 64.4% of the patients treated with IMV [37] . NIV therapy outside the emergency ward or ICU is, however, challenging in Swiss hospitals, and these challenges will need to be addressed before this recommendation can be implemented. 7 Spirometry should be performed before discharging a patient or at least 4-6 weeks thereafter. Patients' lung function should be evaluated before discharge, or at least 4-6 weeks after discharge if this information is not available [36] .
The European COPD Audit has some limitations, such as the lack of information on mucolytics and the vaccination status of the patients. Moreover, the recommended FEV 1 /FVC quotient for diagnosing COPD could overestimate the prevalence of the disease, particularly among elderly people.
In conclusion, considering the overall high standard of health care in Switzerland and in light of the GOLD 2010 guidelines, we were able to make 7 recommendations to improve and standardize the management of severe AECOPD for patients treated in Switzerland.
